Todd Foley
Co-Founder & ChairmanMr. Todd Foley, MBA, is Co-Founder of Aktis Oncology, Inc. and serves as its Chairman since August 2020. He is Co-founder, Chairman of the Board & Director of Crossbow Therapeutics, Inc. Mr. Foley has previously served on the board of directors of Entrada Therapeutics, Inc. (Nasdaq: TRDA). From December 2018 to June 2023, Repare Therapeutics Inc. (Nasdaq: RPTX), from June 2017 to June 2024, Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), from 2014 to June 2021 and Chiasma Inc., from May 2008 until its merger with Amryt Pharma plc in August 2021. He is Director of Seawolf Therapeutics, Inc. Mr. Foley was President of Crossbow Therapeutics, Inc. He is a Managing Director at MPM BioImpact and a co-founder of Crossbow Therapeutics. He has served as Crossbow’s chairman since the company’s inception in 2021. His early career started with management consulting at Arthur D. Little and business development at Genentech (Roche), before moving to MPM Capital (now MPM BioImpact) in 1999. He currently holds additional board positions at a number of private and public biotech company, including Tetherex Pharmaceuticals and previously served on the board of Semma Therapeutics, acquired by Vertex for 950M in 2019 and guided the acquisition of Selexys Pharmaceuticals by Novartis for 665M in 2016.?He earned his B.S. in Chemistry from the Massachusetts Institute of Technology (MIT) and an M.B.A. from Harvard Business School.?.
Positions
- Company NameAktis Oncology, Inc.Stock CodeAKTSPositionCo-Founder & ChairmanColleagues
